The neuropathological diagnosis of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index; 59 of the 135 sources its claims cite were checked for support.
Abstract
Alzheimer's disease is a progressive neurodegenerative disease most often associated with memory deficits and cognitive decline, although less common clinical presentations are increasingly recognized. The cardinal pathological features of the disease have been known for more than one hundred years, and today the presence of these amyloid plaques and neurofibrillary tangles are still required for a pathological diagnosis. Alzheimer's disease is the most common cause of dementia globally. There remain no effective treatment options for the great majority of patients, and the primary causes of the disease are unknown except in a small number of familial cases driven by genetic mutations. Confounding efforts to develop effective diagnostic tools and disease-modifying therapies is the realization that Alzheimer's disease is a mixed proteinopathy (amyloid and tau) frequently associated with other age-related processes such as cerebrovascular disease and Lewy body disease. Defining the relationships between and interdependence of various co-pathologies remains an active area of investigation. This review outlines etiologically-linked pathologic features of Alzheimer's disease, as well as those that are inevitable findings of uncertain significance, such as granulovacuolar degeneration and Hirano bodies. Other disease processes that are frequent, but not inevitable, are also discussed, including pathologic processes that can clinically mimic Alzheimer's disease. These include cerebrovascular disease, Lewy body disease, TDP-43 proteinopathies and argyrophilic grain disease. The purpose of this review is to provide an overview of Alzheimer's disease pathology, its defining pathologic substrates and the related pathologies that can affect diagnosis and treatment.
Overview
CoChat Summary
## TL;DR
This review explains how Alzheimer’s disease is diagnosed neuropathologically, emphasizing that definitive diagnosis requires post-mortem microscopic assessment of amyloid plaques and neurofibrillary tangles plus consideration of common comorbidities. It also highlights that mixed pathology is common and that atypical clinical syndromes can mimic Alzheimer’s disease.
## Key findings
- The definitive diagnosis of AD requires microscopic examination of multiple brain regions, with diagnosis based on lesion morphology, density, and topographic distribution.
- Mixed pathology is common: in the Mayo Clinic Brain Bank data from 2007–2016, the majority of AD cases had coexisting non-Alzheimer pathologies, and comorbidities increased with age.
- In the same brain bank, approximately 16% of AD cases had significant cerebrovascular pathology, and approximately 33% had Lewy-related pathology as a secondary finding.
- Cerebral amyloid angiopathy was estimated to occur in 85–95% of AD cases, and 13% of confirmed AD cases in the Mayo Brain Bank had moderate-to-severe CAA.
- TDP-43 neuronal inclusions were reported in 19–75% of AD cases, and argyrophilic grain disease was reported in up to a quarter of AD cases.
## Methods
- This is a narrative review of Alzheimer’s disease neuropathology, its diagnostic criteria, and frequent co-pathologies.
- The paper draws on prior staging/criteria systems and on Mayo Clinic Brain Bank observations (notably 2007–2016 data) to illustrate frequencies of comorbid pathology and diagnostic pitfalls.
- The main analysis is descriptive and comparative: it synthesizes microscopic features, staging schemes, and neuropathologic criteria (including Thal Aβ phase, Braak NFT stage, CERAD, and the 2012 NIA-AA ABC system).
## Limitations
- Stated in the paper: the authors note that many relationships among co-pathologies remain an “active area of investigation,” and that more research is needed for entities such as Hirano bodies, TDP-43 pathology, and the mechanistic links between pathology and symptoms.
- Stated in the paper: the paper emphasizes that most clinical diagnosis before death is limited because routine access to amyloid/tau biomarkers is lacking and molecular imaging is not reimbursed.
- Evident from the text: this is a review rather than an original empirical study, so its conclusions depend on previously published studies and selected brain bank data rather than a single unified prospective dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
45 Valid · 3 Not valid · 45 Not checked · 20 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Most importantly the neuritic plaques with dense amyloid and tau-positive neurites are believed to be closely associated with neuronal loss and cognitive decline in Alzheimer’s disease [37, 38].”
§ The neuropathological diagnosis of Alzheimer’s disease > Background > Amyloid plaques Senile amyloid plaques or “miliary foci” as described by Alzheimer in the description of Alzheimer’s disease and originally that same year by Oskar Fischer are formed by the extracellular nonvascular accumulation of Aβ40 and Aβ42 peptides that result from the abnormal processing of amyloid precursor protein by the β- and γ-secretases and an imbalance in the production and clearance pathways [1, 27–29]. These small 4 kDa peptides (A4) fold into a beta-pleated sheet structures that are highly fibrillogenic. The Aβ filaments bind congophilic dyes and produce birefringence upon exposure to polarizing light as is characteristic of amyloid [30]. Work using antibodies to A4 protein, now recognized as Aβ peptides, demonstrated they are involved in early formation of amyloid plaques that were not captured with congophilic dyes [31]. Additional Aβ peptides containing between 38 and 43 amino acids are also detected, but Aβ42 is the most fibrillogenic and the predominant component of amyloid plaques in AD [6]. There are many reviews describing the generation of Aβ peptides [32], and these pathways remain viable therapeutic targets. The terminology for Aβ amyloid plaques can be confusing. Nearly a dozen types of nonvascular amyloid deposits have been described, but the two types of amyloid plaques most commonly observed in AD are diffuse plaques and dense core plaques [29, 33] as shown in Fig. 2a, b [23, 29]. Diffuse plaques form initially in the neuropil and stain weakly by thioflavin S and other amyloid binding dyes (e.g., Congo red). They commonly lack argyrophilia on Bodian silver stains, and they do not show preferential accumulation of activated microglia and reactive astrocytes. In comparison, dense core plaques have dense reticular or radiating compact dense amyloid and are intensely positive with thioflavin S fluorescent microscopy and Congo red, suggesting they contain more fibrillogenic forms of Aβ [29, 34, 35]. More importantly, a subset of dense core plaques have neuritic elements as shown in Fig. 2c, d, and these cored neuritic plaques (NPs) can be associated with tau-positive or dystrophic neurites, the latter demonstrated with a variety of markers including synaptic and APP immunohistochemistry [33]. Dense cored NPs are also accompanied by synaptic loss, activated microglia and reactive astrocytes [23, 29, 36]. In contrast, diffuse plaques often lack neuritic components, though diffuse neuritic plaques can be observed in advanced AD [33]. The diffuse plaques are positive with Aβ immunohistochemistry and contain filamentous Aβ at the ultrastructural level, but it is not certain whether diffuse plaques are a part of pathological aging or an early stage in the maturation of neuritic Aβ plaques [29]. Indeed, it appears as many as 8 types of nonvascular amyloid plaque deposits can form after initial deposition of Aβ and that the morphology and type of plaques can vary from region to region [29]. Plaques composed almost exclusively of dense cores lacking neuritic components have been termed “burnt out” plaques [18]. Most importantly the neuritic plaques with dense amyloid and tau-positive neurites are believed to be closely associated with neuronal loss and cognitive decline in Alzheimer’s disease [37, 38].
What the sources say
- Partly supportedcites [37] Malek-Ahmadi M, Perez SE, Chen K, Mufson EJ. Neuritic and diffuse plaque associations with memory in non-cognitively impaired elderly. J Alzheimers Dis. 2016;53:1641–52. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) describes neuritic plaques as containing extracellular amyloid-β and tau and associates them with poorer cognition; it also reports a stronger cognitive association for neuritic than diffuse plaques. It does not establish that the plaques contain *dense* amyloid or that they are closely associated with neuronal loss. (LLM, conf=0.84)
- Disputedcites [38] Knowles RB, Wyart C, Buldyrev SV, Cruz L, Urbanc B, Hasselmo ME, Stanley HE, Hyman BT. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96:5274–9. sourceExperimental — accuracy not yet measured
Our copy states the opposite of the claim's core attribution: the introduction reports 'It has been shown that A b deposits do not correlate with local neuronal loss (7, 8)' and that 'the amount of A b deposits correlates poorly with clinical severity or duration of disease (5-7)' — the paper's whole premise is that plaques act on neurite geometry, not on neuronal loss. The only cognitive link our copy offers runs through neurite morphology, not plaque-burden: RESULTS note 'the presence or absence of cognitive impairment correlates with the presence or absence of changes in neurite morphology,' and the DISCUSSION credits another work (ref 18) for the observation that the percentage of A b deposits associated with dysmorphic neurites rises with duration and severity of dementia. So the 'tau-positive neurite / cognitive decline' element has partial echo, but the 'closely associated with neuronal loss' element attributed to this source is contradicted by it. (LLM, conf=0.72)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More recent studies demonstrate that exogenous Aβ fibrils lead to cell death and disruption of membrane integrity in a cell culture model [41].”
§ The neuropathological diagnosis of Alzheimer’s disease > Background > Neuritic plaques Cored neuritic plaques containing tau-positive neurites usually have a central zone of dense amyloid, sometimes forming a compact core. The dense core can display radiating Aβ fibrils, and it is in these peripheral zones of the plaque where dystrophic neurites and activated microglia are concentrated, that lends credence to the hypothesis that Aβ drives neuronal degeneration and cognitive decline in AD [18, 39]. Neuritic plaques frequently contain activated microglia and reactive astrocytes, and their processes intermingle with neuritic elements in the plaque periphery. Some of the dystrophic neurites associated with neuritic plaques contain tau filaments, which can have a paired helical filament morphology with electron microscopy [23]. These are termed “type 1” dystrophic neurites, and it is suggested they occur in regions receiving input from neurons bearing neurofibrillary tangles in their soma [29, 36]. The dystrophic neurites in neuritic plaques are heterogeneous [36]. In addition to tau-positive neurites, some dystrophic neurites contain neurofilament proteins, suggesting that cytoskeletal changes are part of the neurodegenerative process [40]. Additionally degenerating mitochondria, lysosomal bodies and vesicles, some with ubiquitin-immunoreactivity, can accumulate in a subset of plaque-associated dystrophic neurites, indicating that trafficking and protein degradation pathways are affected [23]. More recent studies demonstrate that exogenous Aβ fibrils lead to cell death and disruption of membrane integrity in a cell culture model [41]. In fact, even the presence of dystrophic neurites, which are postulated to be benign age-related neurites, still provides evidence that amyloid plaques negatively affect the integrity neuronal processes in their vicinity [36]. While dense core neuritic plaques are thought to be more closely associated with neuronal loss in AD [38], diffuse amyloid plaques with neuritic elements are observed in advanced disease though their disease relevance and relationship to the formation of dense core neuritic plaques is not certain [33]. Understanding the links between amyloid-driven neuritic pathology, more widespread tau neuronal and thread pathology, as well as neuronal loss remains an area of active research.
What the sources say
- Partly supportedcites [41] Han S, Kollmer M, Markx D, Claus S, Walther P, Fandrich M. Amyloid plaque structure and cell surface interactions of beta-amyloid fibrils revealed by electron tomography. Sci Rep. 2017;7:43577. sourceExperimental — accuracy not yet measured
The Results section (“Formation of Aβ amyloid plaques in cell culture”; page not provided) reports cell toxicity and membrane damage after exposure to Aβ peptide, with cell death following fibril formation. But the paper describes adding extracellular peptide that cells internalize and convert into amyloid; it does not establish that exogenous, preformed Aβ fibrils caused those effects. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Some of the dystrophic neurites associated with neuritic plaques contain tau filaments, which can have a paired helical filament morphology with electron microscopy [23].”
§ The neuropathological diagnosis of Alzheimer’s disease > Background > Neuritic plaques Cored neuritic plaques containing tau-positive neurites usually have a central zone of dense amyloid, sometimes forming a compact core. The dense core can display radiating Aβ fibrils, and it is in these peripheral zones of the plaque where dystrophic neurites and activated microglia are concentrated, that lends credence to the hypothesis that Aβ drives neuronal degeneration and cognitive decline in AD [18, 39]. Neuritic plaques frequently contain activated microglia and reactive astrocytes, and their processes intermingle with neuritic elements in the plaque periphery. Some of the dystrophic neurites associated with neuritic plaques contain tau filaments, which can have a paired helical filament morphology with electron microscopy [23]. These are termed “type 1” dystrophic neurites, and it is suggested they occur in regions receiving input from neurons bearing neurofibrillary tangles in their soma [29, 36]. The dystrophic neurites in neuritic plaques are heterogeneous [36]. In addition to tau-positive neurites, some dystrophic neurites contain neurofilament proteins, suggesting that cytoskeletal changes are part of the neurodegenerative process [40]. Additionally degenerating mitochondria, lysosomal bodies and vesicles, some with ubiquitin-immunoreactivity, can accumulate in a subset of plaque-associated dystrophic neurites, indicating that trafficking and protein degradation pathways are affected [23]. More recent studies demonstrate that exogenous Aβ fibrils lead to cell death and disruption of membrane integrity in a cell culture model [41]. In fact, even the presence of dystrophic neurites, which are postulated to be benign age-related neurites, still provides evidence that amyloid plaques negatively affect the integrity neuronal processes in their vicinity [36]. While dense core neuritic plaques are thought to be more closely associated with neuronal loss in AD [38], diffuse amyloid plaques with neuritic elements are observed in advanced disease though their disease relevance and relationship to the formation of dense core neuritic plaques is not certain [33]. Understanding the links between amyloid-driven neuritic pathology, more widespread tau neuronal and thread pathology, as well as neuronal loss remains an area of active research.
What the sources say
- Supportedcites [23] Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189. source
The Morphological Characteristics section (page not provided) says electron microscopy revealed that plaque-associated dystrophic neurites often contain paired helical filaments. It also identifies aggregated tau fibrils in these neurites, supporting the claim. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“clinical features lack specificity for a pathologic process, but rather indicate brain regions or systems affected by the disease process [3, 4].”
§ The neuropathological diagnosis of Alzheimer’s disease > Background > Pathology of Alzheimer’s disease
What the sources say
- Partly supportedcites [3] Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785–96. sourceExperimental — accuracy not yet measured
The Discussion (page not available in our copy) links focal clinical presentations in hippocampal-sparing Alzheimer’s disease to selective cortical vulnerability and advises considering Alzheimer’s disease in the differential diagnosis of focal cortical syndromes. This supports the point that symptoms can reflect affected regions, but the study does not establish the broader claim that clinical features generally lack specificity for a pathologic process. (LLM, conf=0.84)
- Partly supportedcites [4] Caselli RJ, Beach TG, Knopman DS, Graff-Radford NR. Alzheimer disease: scientific breakthroughs and translational challenges. Mayo Clin Proc. 2017;92:978–94. sourceExperimental — accuracy not yet measured
The Clinical Background section says that variant Alzheimer syndromes reflect different pathological topography, with visual impairment linked to involvement of visual cortices. That supports the point that clinical features can indicate affected brain regions. The copy does not establish the broader claim that clinical features generally lack specificity for the underlying pathologic process. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senile amyloid plaques or “miliary foci” as described by Alzheimer in the description of Alzheimer’s disease and originally that same year by Oskar Fischer are formed by the extracellular nonvascular accumulation of Aβ40 and Aβ42 peptides that result from the abnormal processing of amyloid precursor protein by the β- and γ-secretases and an imbalance in the production and clearance pathways [1, 27”
§ The neuropathological diagnosis of Alzheimer’s disease > Background > Amyloid plaques Senile amyloid plaques or “miliary foci” as described by Alzheimer in the description of Alzheimer’s disease and originally that same year by Oskar Fischer are formed by the extracellular nonvascular accumulation of Aβ40 and Aβ42 peptides that result from the abnormal processing of amyloid precursor protein by the β- and γ-secretases and an imbalance in the production and clearance pathways [1, 27–29]. These small 4 kDa peptides (A4) fold into a beta-pleated sheet structures that are highly fibrillogenic. The Aβ filaments bind congophilic dyes and produce birefringence upon exposure to polarizing light as is characteristic of amyloid [30]. Work using antibodies to A4 protein, now recognized as Aβ peptides, demonstrated they are involved in early formation of amyloid plaques that were not captured with congophilic dyes [31]. Additional Aβ peptides containing between 38 and 43 amino acids are also detected, but Aβ42 is the most fibrillogenic and the predominant component of amyloid plaques in AD [6]. There are many reviews describing the generation of Aβ peptides [32], and these pathways remain viable therapeutic targets. The terminology for Aβ amyloid plaques can be confusing. Nearly a dozen types of nonvascular amyloid deposits have been described, but the two types of amyloid plaques most commonly observed in AD are diffuse plaques and dense core plaques [29, 33] as shown in Fig. 2a, b [23, 29]. Diffuse plaques form initially in the neuropil and stain weakly by thioflavin S and other amyloid binding dyes (e.g., Congo red). They commonly lack argyrophilia on Bodian silver stains, and they do not show preferential accumulation of activated microglia and reactive astrocytes. In comparison, dense core plaques have dense reticular or radiating compact dense amyloid and are intensely positive with thioflavin S fluorescent microscopy and Congo red, suggesting they contain more fibrillogenic forms of Aβ [29, 34, 35]. More importantly, a subset of dense core plaques have neuritic elements as shown in Fig. 2c, d, and these cored neuritic plaques (NPs) can be associated with tau-positive or dystrophic neurites, the latter demonstrated with a variety of markers including synaptic and APP immunohistochemistry [33]. Dense cored NPs are also accompanied by synaptic loss, activated microglia and reactive astrocytes [23, 29, 36]. In contrast, diffuse plaques often lack neuritic components, though diffuse neuritic plaques can be observed in advanced AD [33]. The diffuse plaques are positive with Aβ immunohistochemistry and contain filamentous Aβ at the ultrastructural level, but it is not certain whether diffuse plaques are a part of pathological aging or an early stage in the maturation of neuritic Aβ plaques [29]. Indeed, it appears as many as 8 types of nonvascular amyloid plaque deposits can form after initial deposition of Aβ and that the morphology and type of plaques can vary from region to region [29]. Plaques composed almost exclusively of dense cores lacking neuritic components have been termed “burnt out” plaques [18]. Most importantly the neuritic plaques with dense amyloid and tau-positive neurites are believed to be closely associated with neuronal loss and cognitive decline in Alzheimer’s disease [37, 38].
What the sources say
- Not checked — no full text of the sourcecites [1] Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat. 1995;8:429–31. source
- Not checked — no full text of the sourcecites [27] Kumar A, Singh A. Ekavali: a review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67:195–203. source
- Partly supportedcites [28] Goedert M. Oskar Fischer and the study of dementia. Brain. 2009;132:1102–11. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [29] Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006. 2006:re1. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims · 11 with their cited sources checked
Create a free account to see all 113 claims and to verify the 9 references still open.
- It may state two separate claims as one. 56
- Probably not a substantial claim. 23
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beta-amyloid (Aβ) plaques and neurofibrillary tau tangles (NFTs) have long been known to be causally related to the cognitive manifestations of Alzheimer’s disease (AD) [19].”
From Enhanced microglial dynamics and a paucity of tau seeding in the amyloid plaque microenvironment contribute to cognitive resilience in Alzheimer’s disease (2024) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Whereas it is well-established that the neuropathological substrates of dementia precede clinical onset (79), a central question is the timing of onset of these molecular changes.”
From Molecular and cellular processes disrupted in the early postnatal Down syndrome prefrontal cortex (2026) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Essential neuropathological hallmarks important for the diagnosis of AD consist of the extracellular deposition of amyloid-β (Aβ) peptides in plaques [1] and intracellular aggregation of hyperphosphorylated Tau protein in neurofibrillary tangles (NFTs) [2].”
From Neuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Neuroinflammation is also linked to neurodegeneration and neuronal loss, which are features that coincidently are associated with amyloid plaque formation (DeTure and Dickson, 2019; Kinney et al., 2018; Sung et al., 2020).”
From Arbovirus infection increases the risk for the development of neurodegenerative disease pathology in the murine model (2024) · cites this paper as DeTure and Dickson, 2019
The cited source says what the claim attributes to it.
In the citing paper
“Neurodegenerative diseases, such as AD and DLB, are often characterized as diseases of protein aggregation (30–33).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [32]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 2×
“Ultimately these criteria were revised in the 2012 NIA-AA Guidelines as it became more universally acknowledged that AD pathology can be present in the absence of clinical symptoms though there are updated clinical guidelines available for ascribing dementia to AD pathology before death [111].”
BackgroundNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“The most widely used staging scheme for tangles was proposed in 1991 by Heiko and Eva Braak [68].”
BackgroundMethodNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“Recommendations for defining the preclinical stages of AD are designed to help improve early and accurate clinical diagnoses for potential therapeutic intervention, and as such these efforts require recognition of amyloid and tau pathology, as well as synaptic loss as substrates for the clinical manifestations of AD […”
BackgroundNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 3×
“Microglial cells are phagocytes that operate within the brain, monitoring their territories for pathogen exposure or deteriorating neurons, which promotes their migration to the site and subsequent activation and at times antigen presentation [84, 85].”
BackgroundClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · cited 1×
“Patients with primary progressive aphasias presenting as agrammatic, semantic or logopenic variants most commonly have frontotemporal lobar degeneration, but hippocampal sparing AD can also present in this manner [7, 102].”
BackgroundMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · cited 1×
“These were subsequently revised in 1991 by the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD), which focused on neuritic plaques in the frontal, temporal and parietal cortices and included clinical presence of dementia to determine if AD was the definite, probable or possible cause of the observed…”
Method
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“145 These results suggest that microglia respond to the pathology of AD.”
BackgroundInfluentialBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Wightman, D. P., Jansen, I. E., Savage, J. E., Shadrin, A. A., Bahrami, S., Holland, D., Rongve, A., Børte, S., Winsvold, B. S., Drange, O. K., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00921-z · Cited by 1,011
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Metadata
- Authors
- DeTure, M. A., & Dickson, D. W.
- Affiliations
- Mayo Clinic in Florida (US)
- Corresponding author
- Dickson, Dennis W.
- Venue
- Molecular Neurodegeneration
- Published
- 2019-08-02
- Volume
- 14
- Issue
- 1
- Pages
- 32-32
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC6679484
- OpenAlex
- W2965717703
- Cited by
- 3,329
- References
- 153
- Citations by year
- 2026: 426 · 2025: 670 · 2024: 654 · 2023: 587 · 2022: 483 · 2021: 356 · 2020: 139 · 2019: 9
- FWCI
- 29.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Alzheimer's Disease Research Center, Emory University (P50 AG16574)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, neuropathological diagnosis, amyloid plaques, neurofibrillary tangles, tau protein, granulovacuolar degeneration, Hirano bodies, cerebrovascular disease, Lewy body disease, TDP-43 proteinopathy, argyrophilic grain disease, dementia, co-pathology
- MeSH terms
- Alzheimer Disease, Brain, Humans, Neurofibrillary Tangles, Neurodegenerative Diseases, Lewy Body Disease, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The neuropathological diagnosis of Alzheimer's disease. https://app.cochat.ai/papers/10.1186/s13024-019-0333-5
- The paper
- DeTure, M. A., & Dickson, D. W. (2019). The neuropathological diagnosis of Alzheimer's disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-019-0333-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.